WORCESTER, Mass., July 10, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, is scheduled to make a poster presentation of clinical data at the 35th Annual Meeting & Exposition of the Controlled Release Society (www.controlledrelease.org) in New York, July 12 - 16, 2008.
On Monday, July 14, 2008, a poster presentation will be made, on behalf of Generex, of an abstract entitled "Basal and Pre-Prandial Insulin Analogue Injections vs. Basal Human Insulin Injection and Prandial Oral Insulin (Generex Oral-lyn(tm)) in Type-1 Diabetes Mellitus: A 372-Day Comparison." The abstract was co-authored by Doctors J. Guevara-Aguirre, M. Guevara-Aguirre, and J. Saavedra, each of the Institute of Endocrinology IEMYR; Professor Arlan L. Rosenbloom of the University of Florida; and Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs.
The 372-day study concluded that a regimen of twice-daily basal human insulin injections plus prandial applications of Generex Oral-lyn achieved lower pre-meal glucose, HbA1c, and Fructosamine concentrations when compared to a regimen using basal and pre-prandial insulin analogue injections in patients with Type-1 diabetes mellitus.
The Controlled Release Society (CRS) is an international organization that serves three thousand members from more than fifty countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government. CRS is the premier multidisciplinary society dedicated to promoting the science, technology, and innovation of delivery of bio-actives for the benefit of the world population.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.